Clinical Trial Update: A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer Participants With Exocrine Pancreatic Insufficiency (EPI) [Phase 4]

View source ↗

Summary

Phase 4 trial of Creon (pancrelipase) in pancreatic cancer patients with exocrine pancreatic insufficiency has been terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Exocrine Pancreatic Insufficiency
• Pancreatic Cancer

Drugs mentioned

• Creon (pancrelipase)

Snippet

Sponsor: AbbVie | Conditions: Exocrine Pancreatic Insufficiency (EPI) | Phase 4 | Status: TERMINATED | Results posted: 2023-06-05